Noxopharm Ltd (ASX:NOX) has been granted a trading halt by the ASX, pending details clarifying the company’s position on an ASX release made by Kazia Therapeutics Ltd after close of trading on 22 November 2017.
Kazia (ASX:NRTDA;NASDAQ:NVGN) was formally known as Novogen Ltd.
Kazia noted to the ASX that it seeks to provide clarification regarding a recent media report referring to Noxopharm and its managing director and chief executive officer, Dr Graham Kelly, and a former chief executive officer of the company.
The company will now look to provide details regarding the company's intellectual property position.
The halt will remain in place until the opening of trade on Monday 27th November 2017, or earlier if an announcement is made to the market.